Pregled novosti o zdravlju i dugovječnosti — 19. listopada 2026.Health & longevity news — 19 October 2026
Tjedan je obilježila nova generacija „satova starenja” i provjera koliko im smijemo vjerovati. U časopisu Science, grupa s Arizona State University objavila je epigenetski sat za pse (Dog Aging Project, 894 psa): veći psi i mužjaci stare brže na molekularnoj razini, a oni čija je biološka dob viša od očekivane imaju veći rizik ranije smrti. Kod ljudi, presječna analiza INSPIRE-t kohorte (890 odraslih, 20–102 g.) pokazuje da tjelesna aktivnost ublažava štetan učinak lošeg sna i dugog sjedenja na satove GrimAge, DunedinPACE i iAge. Velika meta-analiza u Lancet Healthy Longevity (13.851 sudionik) povezuje gubitak sluha s većom smrtnošću, uz naznaku da slušna pomagala taj rizik umanjuju. U pozadini: industrijski novac ulazi u starenje (NewLimit 435 mil. USD, Retro, veliki farma igrači), dok struka na konferenciji o biomarkerima starenja gura standardizaciju i oprez prije „anti-aging” tvrdnji.The week was defined by a new wave of "aging clocks" and a hard look at how far to trust them. In Science, an Arizona State University group published an epigenetic clock for dogs (Dog Aging Project, 894 dogs): larger dogs and males age faster at the molecular level, and dogs whose biological age runs ahead face higher risk of early death. In humans, a cross-sectional analysis of the INSPIRE-t cohort (890 adults, 20–102 y) shows physical activity buffers the harm that poor sleep and prolonged sitting do to the GrimAge, DunedinPACE and iAge clocks. A large Lancet Healthy Longevity meta-analysis (13,851 participants) links hearing loss to higher mortality, with a signal that hearing aids lower that risk. In the background: industry money is pouring into aging (NewLimit's $435M, Retro, big pharma), while the field pushes standardization and caution before "anti-aging" claims.
NajvažnijeHighlights
- Veći psi stare brže — epigenetski sat predviđa raniju smrt (Science, Dog Aging Project)Bigger dogs age faster — an epigenetic clock predicts earlier death (Science, Dog Aging Project)
- Tjelesna aktivnost ublažava štetu lošeg sna i sjedenja na satovima starenja (890 odraslih)Physical activity buffers the harm of poor sleep and sitting on aging clocks (890 adults)
- Gubitak sluha povezan s većom smrtnošću; slušna pomagala umanjuju rizik (meta-analiza, 13.851 osoba)Hearing loss linked to higher mortality; hearing aids lower the risk (meta-analysis, 13,851 people)
A) Istraživanja na ljudimaA) Research in humans
- Gubitak sluha povezan s većom smrtnošću, a slušna pomagala s manjim rizikomHearing loss tied to higher mortality, hearing-aid use to lower risk (pregledni radreview)
- Tjelesna aktivnost „gasi” štetu lošeg sna i dugog sjedenja na satovima biološke dobiPhysical activity offsets the damage of poor sleep and prolonged sitting on biological-age clocks (potvrđeno (ljudi)confirmed (human))
- Epigenetski satovi trebaju „provjeru stvarnosti” prije anti-aging tvrdnjiEpigenetic clocks need a reality check before anti-aging claims (pregledni radreview)
B) Istraživanja na životinjamaB) Research in animals
- Veći psi stare brže na epigenetskoj razini — sat procjenjuje dob unutar ~godinu danaLarger dogs age faster epigenetically — the clock estimates age within ~1 year (pretklinički (životinje)preclinical (animal))
- Butirat (metabolit crijevnih bakterija) obećava protiv fibroze — zasad u modelimaButyrate (a gut-microbe metabolite) shows antifibrotic promise — so far in models (pretklinički (životinje)preclinical (animal))
C) Vijesti iz industrijeC) Industry news
- NewLimit prikupio 435 mil. USD za prve ljudske pokuse „reprogramiranja” stanične dobiNewLimit raised $435M for first human trials of cell-age "reprogramming" (industrijaindustry)
- Retro Biosciences: lijek RTR242 u Fazi 1, vrednovanje ~1,8 mlrd. USDRetro Biosciences: RTR242 in Phase 1, valued at ~$1.8B (industrija / rana klinička fazaindustry / early clinical)
- Velika farmacija sve ozbiljnije tretira starenje kao metu lijekaBig pharma increasingly treats aging as a drug target (industrijaindustry)
- Konferencija o biomarkerima starenja (Harvard) gura standardizaciju i validacijuBiomarkers of Aging Conference (Harvard) pushes standardization and validation (industrijaindustry)
A) Istraživanja na ljudimaA) Research in humans
Gubitak sluha povezan s većom smrtnošću, a slušna pomagala s manjim rizikomHearing loss tied to higher mortality, hearing-aid use to lower risk
Što se dogodilo: Meta-analiza individualnih podataka iz tri populacijske studije (Australija, Island, SAD; 13.851 sudionik, replikacija u Norveškoj), objavljena u Lancet Healthy Longevity, pokazuje porast rizika smrti s težinom gubitka sluha: blagi HR 1,19, umjereni 1,55, teži 1,56. Korištenje slušnih pomagala povezano je s nižim rizikom.What happened: An individual-participant-data meta-analysis of three population studies (Australia, Iceland, USA; 13,851 participants, replicated in Norway) in Lancet Healthy Longevity shows mortality risk rising with hearing-loss severity: mild HR 1.19, moderate 1.55, moderately severe-or-worse 1.56. Hearing-aid use was associated with lower risk.
Zašto je važno: Sluh je često zanemaren čimbenik zdravog starenja; podaci sugeriraju da je njegova korekcija jednostavna, a potencijalno važna poluga za dulji život i očuvanje funkcije.Why it matters: Hearing is an often-overlooked lever of healthy aging; the data suggest correcting it is simple yet potentially meaningful for longevity and preserved function.
Praktično: Provjera sluha i pravovremena upotreba pomagala razumna su mjera, osobito nakon 60. godine. (Nije medicinski savjet.)In practice: A hearing check and timely aid use are sensible, especially after age 60. (Not medical advice.)
Tjelesna aktivnost „gasi” štetu lošeg sna i dugog sjedenja na satovima biološke dobiPhysical activity offsets the damage of poor sleep and prolonged sitting on biological-age clocks
Što se dogodilo: Presječna analiza INSPIRE-t kohorte (890 odraslih, 20–102 g.), objavljena u GeroScience, pokazuje da je viša razina tjelesne aktivnosti ublažavala negativnu vezu lošeg sna i dugog sjedenja s ubrzanjem satova GrimAge, DunedinPACE, iAge i mjere intrinzičnog kapaciteta. Riječ je o opservacijskim (presječnim) podacima, ne o dokazu uzročnosti.What happened: A cross-sectional analysis of the INSPIRE-t cohort (890 adults, 20–102 y) in GeroScience shows higher physical activity attenuated the adverse links of poor sleep and prolonged sitting with acceleration of the GrimAge, DunedinPACE, iAge and intrinsic-capacity clocks. These are observational (cross-sectional) data, not proof of causation.
Zašto je važno: Za kineziologiju i sport ključna poruka: kretanje ne djeluje izolirano — kombinacija aktivnosti, manje sjedenja i kvalitetnog sna najbolje čuva biološku dob.Why it matters: For kinesiology and sport the key message: movement does not act in isolation — combining activity, less sitting and good sleep best protects biological age.
Praktično: Cilj nije samo „više treninga” nego i prekidanje sjedenja i briga o snu — paket koji se međusobno pojačava.In practice: The goal is not just "more training" but also breaking up sitting and protecting sleep — a mutually reinforcing package.
Epigenetski satovi trebaju „provjeru stvarnosti” prije anti-aging tvrdnjiEpigenetic clocks need a reality check before anti-aging claims
Što se dogodilo: Analize ovog tjedna upozoravaju da tvrdnje o „pomlađivanju” izvedene iz jednog epigenetskog sata često ne prolaze kad se provjere s više satova; predlažu se kriteriji za razlikovanje stvarnog signala starenja od šuma.What happened: This week's analyses warn that "rejuvenation" claims from a single epigenetic clock often fail when cross-checked against multiple clocks; criteria are proposed to separate a real aging signal from noise.
Zašto je važno: Tržište testova biološke dobi raste brže od njihove validacije; ovo je važan podsjetnik na opreznost pri tumačenju komercijalnih rezultata.Why it matters: The biological-age testing market is growing faster than its validation; a timely reminder to interpret commercial results with caution.
Praktično: Rezultat jednog „sata starenja” tretirajte kao orijentir, ne kao dijagnozu; trend kroz vrijeme znači više od jedne brojke.In practice: Treat a single "aging clock" result as a signpost, not a diagnosis; a trend over time means more than one number.
B) Istraživanja na životinjamaB) Research in animals
Veći psi stare brže na epigenetskoj razini — sat procjenjuje dob unutar ~godinu danaLarger dogs age faster epigenetically — the clock estimates age within ~1 year
Što se dogodilo: Studija u časopisu Science (8.10.2026., Arizona State University) izgradila je epigenetski sat iz metilacije DNA u krvi 894 psa iz Dog Aging Projecta. Medijalna pogreška procjene dobi je oko godinu dana; veći psi i mužjaci pokazuju ubrzano starenje, a viša biološka dob povezana je s većim rizikom ranije smrti. Signal je povezan s regijama DNA koje inače obuzdavaju pokretne genetske elemente.What happened: A Science study (8 Oct 2026, Arizona State University) built an epigenetic clock from blood DNA methylation in 894 dogs from the Dog Aging Project. Median age-estimation error is about one year; larger dogs and males show accelerated aging, and higher biological age is linked to greater risk of early death. The signal involves DNA regions that normally suppress mobile genetic elements.
Zašto je važno: Psi dijele okoliš i mnoge bolesti sa svojim vlasnicima, pa su moćan model za ljudsko starenje; veličina tijela kao ubrzivač starenja zanimljiva je paralela s rastom i IGF-signalizacijom.Why it matters: Dogs share our environment and many diseases, making them a powerful model for human aging; body size as an aging accelerator is an intriguing parallel to growth and IGF signaling.
Butirat (metabolit crijevnih bakterija) obećava protiv fibroze — zasad u modelimaButyrate (a gut-microbe metabolite) shows antifibrotic promise — so far in models
Što se dogodilo: Pregledni rad u Ageing Research Reviews sažima sve brojnije pretkliničke dokaze da butirat, glavni metabolit crijevne mikrobiote, ublažava fibrozu jetre, bubrega, pluća i srca kroz epigenetske i protuupalne mehanizme. Dokazi su pretežno iz životinjskih modela; klinička primjena tek predstoji.What happened: A review in Ageing Research Reviews summarizes growing preclinical evidence that butyrate, a major gut-microbiota metabolite, mitigates fibrosis of liver, kidney, lung and heart via epigenetic and anti-inflammatory mechanisms. Evidence is mostly from animal models; clinical use is still ahead.
Zašto je važno: Fibroza (ožiljkavanje tkiva) raste sa starenjem i podloga je mnogih bolesti; veza prehrana–mikrobiom–starenje sve je relevantnija i za sportsku fiziologiju oporavka.Why it matters: Fibrosis (tissue scarring) rises with age and underlies many diseases; the diet–microbiome–aging link is increasingly relevant, including for recovery physiology in sport.
C) Vijesti iz industrijeC) Industry news
NewLimit prikupio 435 mil. USD za prve ljudske pokuse „reprogramiranja” stanične dobiNewLimit raised $435M for first human trials of cell-age "reprogramming"
Što se dogodilo: NewLimit (suosnivač Brian Armstrong) zatvorio je Series C od 435 mil. USD za financiranje prvog ljudskog ispitivanja terapije djelomičnog epigenetskog reprogramiranja; prvi cilj je masna bolest jetre, s planom Faze I iduće godine. Dio izvještaja navodi procjenu vrijednosti ~3,1 mlrd. USD (nepotvrđeno).What happened: NewLimit (co-founded by Brian Armstrong) closed a $435M Series C to fund its first human trial of partial epigenetic-reprogramming therapy; the initial target is fatty liver disease, with a Phase I planned next year. Some reports cite a ~$3.1B valuation (unconfirmed).
Zašto je važno: Reprogramiranje je najambiciozniji pravac rejuvenacije; ulazak u kliniku testirat će hoće li spektakularni laboratorijski rezultati izdržati sigurnosne i regulatorne pragove.Why it matters: Reprogramming is the most ambitious rejuvenation avenue; entering the clinic will test whether spectacular lab results survive safety and regulatory thresholds.
Retro Biosciences: lijek RTR242 u Fazi 1, vrednovanje ~1,8 mlrd. USDRetro Biosciences: RTR242 in Phase 1, valued at ~$1.8B
Što se dogodilo: Retro Biosciences navodi da je njihov vodeći kandidat RTR242 (mehanizam poticanja autofagije) od odabira indikacije do prvog doziranja u ljudi stigao za 15 mjeseci i sada je u Fazi 1; tvrtka je nedavno prikupila sredstva uz procjenu ~1,8 mlrd. USD.What happened: Retro Biosciences says its lead candidate RTR242 (an autophagy-stimulating mechanism) went from indication selection to first-in-human dosing in 15 months and is now in Phase 1; the company recently raised financing at a ~$1.8B valuation.
Zašto je važno: Autofagija (stanično „čišćenje”) je i jedan od mehanizama koristi tjelovježbe i posta — klinički dokaz lijeka koji je cilja bio bi relevantan i izvan longevity niše.Why it matters: Autophagy (cellular "clean-up") is also one mechanism behind the benefits of exercise and fasting — clinical proof of a drug targeting it would matter beyond the longevity niche.
Velika farmacija sve ozbiljnije tretira starenje kao metu lijekaBig pharma increasingly treats aging as a drug target
Što se dogodilo: Niz suradnji signalizira zaokret: BioAge s Novartisom, Insilico Medicine s Eli Lillyjem (uplata ~115 mil. USD unaprijed), Gero s Chugaijem (Roche grupa, do ~250 mil. USD u miljokazima). Uz to, Matchpoint Therapeutics zatvorio je 150 mil. USD Series B (7.10.2026.) uz longevity-usmjerene ulagače.What happened: A string of deals signals a shift: BioAge with Novartis, Insilico Medicine with Eli Lilly (~$115M upfront), Gero with Chugai (Roche group, up to ~$250M in milestones). Matchpoint Therapeutics also closed a $150M Series B (7 Oct 2026) backed by longevity-focused investors.
Zašto je važno: Ulazak velikih igrača donosi kapital i regulatornu ozbiljnost, ali i pritisak da se „starenje kao bolest” tek dokaže kliničkim ishodima, ne samo biomarkerima.Why it matters: Big players bring capital and regulatory seriousness, but also pressure to actually prove "aging as a disease" through clinical outcomes, not just biomarkers.
Konferencija o biomarkerima starenja (Harvard) gura standardizaciju i validacijuBiomarkers of Aging Conference (Harvard) pushes standardization and validation
Što se dogodilo: Na konferenciji o biomarkerima starenja (Harvard, 5.–6.10.) istraživači i regulatori, uključujući ARPA-H program PROSPR, radili su na standardiziranim, klinički validiranim mjerama biološke dobi — preduvjetu za ozbiljna ispitivanja geroprotektora.What happened: At the Biomarkers of Aging Conference (Harvard, 5–6 Oct), researchers and regulators, including ARPA-H's PROSPR program, worked toward standardized, clinically validated measures of biological age — a prerequisite for serious geroprotector trials.
Zašto je važno: Bez dogovorenih, validiranih mjera starenja nema pouzdane procjene djeluje li neka intervencija; ovo je infrastruktura koja odvaja znanost od marketinga.Why it matters: Without agreed, validated aging measures there is no reliable way to tell whether an intervention works; this is the infrastructure that separates science from marketing.
Izvori: PubMed, Science, Lancet Healthy Longevity, GeroScience, Ageing Research Reviews te vodeći longevity portali. Znanstveni radovi (DOI): · 10.1016/j.lanhl.2026.100903 · 10.1007/s11357-026-02592-2 · 10.1016/j.arr.2026.103413Sources: PubMed, Science, Lancet Healthy Longevity, GeroScience, Ageing Research Reviews and leading longevity outlets. Research papers (DOI): · 10.1016/j.lanhl.2026.100903 · 10.1007/s11357-026-02592-2 · 10.1016/j.arr.2026.103413
Napomena: sadržaj je isključivo informativne i edukativne naravi i ne predstavlja medicinski savjet. Za zdravstvene odluke posavjetujte se s liječnikom ili drugim kvalificiranim stručnjakom.Note: this content is for information and education only and is not medical advice. For any health decision, consult a physician or other qualified professional.